US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Kiromic BioPharma, Inc. - Common Stock
(NQ:
KRBP
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 13, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kiromic BioPharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
May 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024
↗
May 13, 2024
Kiromic BioPharma just reported results for the first quarter of 2024.
Via
InvestorPlace
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
April 24, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 02, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
March 01, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
Live and Archived Fireside Chat Available at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 29, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
January 05, 2024
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
December 14, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 16, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 09, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
October 23, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 13, 2023
Via
Benzinga
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
September 13, 2023
From
Kiromic BioPharma
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
↗
August 01, 2023
On Tuesday, 46 stocks hit new 52-week lows.
Via
Benzinga
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023
From
Kiromic BioPharma, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
↗
July 28, 2023
Friday's session saw 59 companies set new 52-week lows.
Via
Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 30, 2023
Via
Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
↗
June 30, 2023
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
June 30, 2023
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today!
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
June 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 10, 2023
Via
Benzinga
What's Going On With Kiromic BioPharma Stock Wednesday
↗
May 03, 2023
Kiromic BioPharma Inc (NASDAQ: KRBP) shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
